These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24322664)

  • 1. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 2. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
    Amiri-Kordestani L; Wedam S; Zhang L; Tang S; Tilley A; Ibrahim A; Justice R; Pazdur R; Cortazar P
    Clin Cancer Res; 2014 Nov; 20(21):5359-64. PubMed ID: 25204553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA advisory panel recommends approval of drug for preoperative treatment of breast cancer.
    Jin J
    JAMA; 2013 Oct; 310(14):1434. PubMed ID: 24104359
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
    Howie LJ; Scher NS; Amiri-Kordestani L; Zhang L; King-Kallimanis BL; Choudhry Y; Schroeder J; Goldberg KB; Kluetz PG; Ibrahim A; Sridhara R; Blumenthal GM; Pazdur R; Beaver JA
    Clin Cancer Res; 2019 May; 25(10):2949-2955. PubMed ID: 30552112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
    Kaklamani VG; Gradishar WJ
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1448-52. PubMed ID: 26553770
    [No Abstract]   [Full Text] [Related]  

  • 12. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
    Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
    Gerratana L; Bonotto M; Bozza C; Ongaro E; Fanotto V; Pelizzari G; Puglisi F
    Expert Opin Biol Ther; 2017 Mar; 17(3):365-374. PubMed ID: 28092723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beautiful history of pertuzumab.
    Perez-Garcia J; Muñoz-Couselo E; Ortega V; Cortes J
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):703-5. PubMed ID: 22716485
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
    Abair T; O'Shaughnessy J
    Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832
    [No Abstract]   [Full Text] [Related]  

  • 20. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.